Skip to content
TrialScanner

NCT02923531

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Phase 1/Phase 2TerminatedXFORLead

Registry record

Lead sponsor
X4 Pharmaceuticals
Conditions
Clear Cell Renal Cell Carcinoma
Primary completion
Aug 8, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02923531 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02923531: Addition of X4P-001 to... | TrialScanner